SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-21-046965
Filing Date
2021-09-08
Accepted
2021-09-08 09:01:22
Documents
45
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT OF PRIVATE ISSUER ea146756-6k_altamira.htm   iXBRL 6-K 23092
2 UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS ea146756ex99-1_altamira.htm   iXBRL EX-99.1 282997
3 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERA ea146756ex99-2_altamirathera.htm EX-99.2 135397
4 PRESS RELEASE DATED SEPTEMBER 8, 2021 ea146756ex99-3_altamirathera.htm EX-99.3 93117
  Complete submission text file 0001213900-21-046965.txt   2442948

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE ears-20210630.xsd EX-101.SCH 45827
6 XBRL CALCULATION FILE ears-20210630_cal.xml EX-101.CAL 32654
7 XBRL DEFINITION FILE ears-20210630_def.xml EX-101.DEF 125246
8 XBRL LABEL FILE ears-20210630_lab.xml EX-101.LAB 263074
9 XBRL PRESENTATION FILE ears-20210630_pre.xml EX-101.PRE 132940
10 EXTRACTED XBRL INSTANCE DOCUMENT ea146756-6k_altamira_htm.xml XML 176495
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON HM 11 D0 00000
Business Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON HM 11 D0 00000 41 (0) 41 729 71 94
Altamira Therapeutics Ltd. (Filer) CIK: 0001601936 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36582 | Film No.: 211240851
SIC: 2834 Pharmaceutical Preparations